Your session is about to expire
← Back to Search
Alpha Particle Radiotherapy for Eye Cancer
Study Summary
This trial is testing a new drug to treat uveal melanoma, a type of eye cancer. They want to find the highest dose of the drug that people can tolerate, and also learn more about how the drug works in the body and what side effects it causes.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have previously received alpha-particle therapy.I do not have any severe illnesses or social situations that would stop me from following the study's requirements.My blood tests show normal organ function.I agree to use two forms of birth control during and up to 3 months after treatment.I am not pregnant or nursing, and if capable of childbearing, I have a recent negative pregnancy test.I have stable brain metastases, not including carcinomatous meningitis, and am on low-dose steroids or none.I have had radiation therapy to over 25% of my bone marrow.My uveal melanoma has worsened after at least one treatment.I am 18 years old or older.I am not immunocompromised due to HIV, certain conditions, or high-dose steroids.I have another active cancer that needs treatment and could affect my melanoma study results.You need to have a disease that can be measured according to specific medical guidelines.I am fully active or can carry out light work.My cancer is a type of melanoma that started in the eye and has spread.
- Group 1: 225Ac-MTI-201 254 microCi
- Group 2: 225Ac-MTI-201 998 microCi
- Group 3: 225Ac-MTI-201 750 microCi
- Group 4: 225Ac-MTI-201 424 microCi
- Group 5: 225Ac-MTI-201 564 microCi
- Group 6: 225Ac-MTI-201 1327 microCi
- Group 7: 225Ac-MTI-201 19 microCi
- Group 8: 225Ac-MTI-201 38 microCi
- Group 9: 225Ac-MTI-201 76 microCi
- Group 10: 225Ac-MTI-201 152 microCi
- Group 11: 225Ac-MTI-201 4.7 microCi
- Group 12: 225Ac-MTI-201 9.5 microCi
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the 4.7 microCi 225Ac-MTI-201 received regulatory authorization from the FDA?
"Our team at Power has assigned a score of 1 to 4.7 microCi 225Ac-MTI-201, as this is an experimental drug and there exists only minimal clinical evidence for its safety or efficacy."
How many individuals are partaking in the examination of this clinical experiment?
"Affirmative. According to the details furnished on clinicaltrials.gov, this trial is still recruiting participants and was originally posted on July 21st 2022; with its most recent update occuring August 9th 2022. Currently, 16 patients are needed from a single medical centre for enrolment in this study."
Are there still opportunities to partake in this scientific experiment?
"According to the details hosted on clinicaltrials.gov, this research initiative is still recruiting participants; first posted in July of 2022 and updated recently at the start of August."
Share this study with friends
Copy Link
Messenger